These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16340185)

  • 1. Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.
    Warach S; Kaufman D; Chiu D; Devlin T; Luby M; Rashid A; Clayton L; Kaste M; Lees KR; Sacco R; Fisher M;
    Cerebrovasc Dis; 2006; 21(1-2):106-11. PubMed ID: 16340185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.
    Sacco RL; DeRosa JT; Haley EC; Levin B; Ordronneau P; Phillips SJ; Rundek T; Snipes RG; Thompson JL;
    JAMA; 2001 Apr; 285(13):1719-28. PubMed ID: 11277826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.
    Lees KR; Asplund K; Carolei A; Davis SM; Diener HC; Kaste M; Orgogozo JM; Whitehead J
    Lancet; 2000 Jun; 355(9219):1949-54. PubMed ID: 10859040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.
    Haley EC; Thompson JL; Levin B; Davis S; Lees KR; Pittman JG; DeRosa JT; Ordronneau P; Brown DL; Sacco RL;
    Stroke; 2005 May; 36(5):1006-10. PubMed ID: 15831831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II studies of the glycine antagonist GV150526 in acute stroke : the North American experience. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators.
    Stroke; 2000 Feb; 31(2):358-65. PubMed ID: 10657406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
    Lees KR; Lavelle JF; Cunha L; Diener HC; Sanders EA; Tack P; Wester P;
    Cerebrovasc Dis; 2001; 11(1):20-9. PubMed ID: 11173790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
    Aslanyan S; Fazekas F; Weir CJ; Horner S; Lees KR;
    Stroke; 2003 Oct; 34(10):2420-5. PubMed ID: 14500934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial.
    Kidwell CS; Lees KR; Muir KW; Chen C; Davis SM; De Silva DA; Weir CJ; Starkman S; Alger JR; Saver JL;
    Stroke; 2009 May; 40(5):1704-9. PubMed ID: 19299636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.
    Warach S; Pettigrew LC; Dashe JF; Pullicino P; Lefkowitz DM; Sabounjian L; Harnett K; Schwiderski U; Gammans R
    Ann Neurol; 2000 Nov; 48(5):713-22. PubMed ID: 11079534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke.
    Hoke JF; Dyker AG; Barnaby RJ; Lees KR
    Eur J Clin Pharmacol; 2000; 55(11-12):867-72. PubMed ID: 10805066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.
    Smith EE; Shoamanesh A; Xu L; Heenan L; Saad F; Colorado P; Chen CH; Lemmens R; De Marchis GM; Caso V; Masjuan J; Hirano T; Milanov I; Campbell BCV; Mas JL; Connolly SJ; Mundl H; Hart RG;
    Stroke; 2024 Feb; 55(2):392-402. PubMed ID: 38174569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care resource use and stroke outcome. Multinational comparisons within the GAIN International trial.
    Asplund K; Ashburner S; Cargill K; Hux M; Lees K; Drummond M;
    Int J Technol Assess Health Care; 2003; 19(2):267-77. PubMed ID: 12862185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point.
    Ebinger M; Christensen S; De Silva DA; Parsons MW; Levi CR; Butcher KS; Bladin CF; Barber PA; Donnan GA; Davis SM;
    Stroke; 2009 Apr; 40(4):1353-8. PubMed ID: 19246703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.
    Hougaard KD; Hjort N; Zeidler D; Sørensen L; Nørgaard A; Thomsen RB; Jonsdottir K; Mouridsen K; Hansen TM; Cho TH; Nielsen TT; Bøtker HE; Østergaard L; Andersen G
    Int J Stroke; 2013 Feb; 8(2):141-6. PubMed ID: 22463392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial.
    Hougaard KD; Hjort N; Zeidler D; Sørensen L; Nørgaard A; Hansen TM; von Weitzel-Mudersbach P; Simonsen CZ; Damgaard D; Gottrup H; Svendsen K; Rasmussen PV; Ribe LR; Mikkelsen IK; Nagenthiraja K; Cho TH; Redington AN; Bøtker HE; Østergaard L; Mouridsen K; Andersen G
    Stroke; 2014 Jan; 45(1):159-67. PubMed ID: 24203849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke.
    Dyker AG; Lees KR
    Stroke; 1999 May; 30(5):986-92. PubMed ID: 10229732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early infarct growth predicts long-term clinical outcome in ischemic stroke.
    Kim SM; Kwon SU; Kim JS; Kang DW
    J Neurol Sci; 2014 Dec; 347(1-2):205-9. PubMed ID: 25304056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat.
    Bordi F; Pietra C; Ziviani L; Reggiani A
    Exp Neurol; 1997 Jun; 145(2 Pt 1):425-33. PubMed ID: 9217078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiphasic perfusion computed tomography in hyperacute ischemic stroke: comparison with diffusion and perfusion magnetic resonance imaging.
    Na DG; Ryoo JW; Lee KH; Moon CH; Yi CA; Kim EY; Lee SJ; Yi BY; Kim JH; Byun HS
    J Comput Assist Tomogr; 2003; 27(2):194-206. PubMed ID: 12703012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.